Genus (GNS) Stock Overview
Produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GNS Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Genus plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£22.74 |
| 52 Week High | UK£32.29 |
| 52 Week Low | UK£18.90 |
| Beta | 0.90 |
| 1 Month Change | -4.29% |
| 3 Month Change | -14.83% |
| 1 Year Change | 14.27% |
| 3 Year Change | -6.42% |
| 5 Year Change | -57.18% |
| Change since IPO | 1,584.44% |
Recent News & Updates
Narrative Update • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.
Narrative Update • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.Narrative Update • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.
Narrative Update • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.Narrative Update • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.Recent updates
Narrative Update • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.Narrative Update • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.Narrative Update • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.Narrative Update • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.Narrative Update • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.Narrative Update • Mar 06
GNS: China JV And Gene Editing Progress Will Support Medium Term Upside
Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.Narrative Update • Feb 20
GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside
Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.Narrative Update • Feb 06
GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook
Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.Narrative Update • Jan 23
GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential
Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.Narrative Update • Jan 08
GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk
Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.Analysis Article • Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£21.95 based on 2 Stage Free Cash Flow to Equity Current share price of...Narrative Update • Dec 22
GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks
Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.Narrative Update • Dec 08
GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks
Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.Narrative Update • Nov 24
GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns
Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.Analysis Article • Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Genus plc ( LON:GNS ) is definitely a stock worth...Analysis Article • Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217
Genus plc's ( LON:GNS ) investors are due to receive a payment of £0.217 per share on 5th of December. Including this...Analysis Article • Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit
Genus plc's ( LON:GNS ) solid earnings announcement recently didn't do much to the stock price. Our analysis suggests...Analysis Article • Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of December. This means...Narrative Update • Sep 10
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.Analysis Article • Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of...Analysis Article • Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Despite an already strong run, Genus plc ( LON:GNS ) shares have been powering on, with a gain of 25% in the last...Analysis Article • Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights The projected fair value for Genus is UK£25.58 based on 2 Stage Free Cash Flow to Equity Genus' UK£24.10...Analysis Article • May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Genus plc ( LON:GNS ) shareholders would be excited to see that the share price has had a great month, posting a 36...Analysis Article • Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
Key Insights The projected fair value for Genus is UK£20.55 based on 2 Stage Free Cash Flow to Equity Genus is...
New Narrative • Feb 11
Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position
Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.Analysis Article • Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Genus plc ( LON:GNS ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last month...Analysis Article • Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S
Genus plc's ( LON:GNS ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a strong buy right now compared...Analysis Article • Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
Genus plc ( LON:GNS ) will pay a dividend of £0.217 on the 6th of December. This payment means the dividend yield will...Analysis Article • Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings
The market for Genus plc's ( LON:GNS ) shares didn't move much after it posted weak earnings recently. We did some...Analysis Article • Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next
Genus plc ( LON:GNS ) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to UK£17.10...Analysis Article • Jun 16
The Price Is Right For Genus plc (LON:GNS)
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right now...Analysis Article • Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£18.59 based on 2 Stage Free Cash Flow to Equity Genus' UK£17.18 share...Analysis Article • Mar 25
Is Genus (LON:GNS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For
Genus plc ( LON:GNS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The drop...Analysis Article • Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.103 per share on the 28th of March. The dividend...Analysis Article • Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 44x might make it look like a strong sell right now...Analysis Article • Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?
Key Insights The projected fair value for Genus is UK£15.63 based on 2 Stage Free Cash Flow to Equity Genus is...Shareholder Returns
| GNS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.3% | -4.1% | -0.6% |
| 1Y | 14.3% | 16.8% | 17.3% |
Return vs Industry: GNS underperformed the UK Biotechs industry which returned 16.8% over the past year.
Return vs Market: GNS underperformed the UK Market which returned 17.3% over the past year.
Price Volatility
| GNS volatility | |
|---|---|
| GNS Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.8% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: GNS has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: GNS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 3,190 | JK Kokke | www.genusplc.com |
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand.
Genus plc Fundamentals Summary
| GNS fundamental statistics | |
|---|---|
| Market cap | UK£1.52b |
| Earnings (TTM) | UK£47.50m |
| Revenue (TTM) | UK£672.00m |
32.0x
P/E Ratio2.3x
P/S RatioIs GNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNS income statement (TTM) | |
|---|---|
| Revenue | UK£672.00m |
| Cost of Revenue | UK£402.40m |
| Gross Profit | UK£269.60m |
| Other Expenses | UK£222.10m |
| Earnings | UK£47.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 10, 2026
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 40.12% |
| Net Profit Margin | 7.07% |
| Debt/Equity Ratio | 46.4% |
How did GNS perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 17:25 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genus plc is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Chantry | Berenberg |
| Matthew Lloyd | BNP Paribas |
| Alexander Jones | BofA Global Research |